FDA clears Johnson & Johnson’s Icotyde for plaque psoriasis

Johnson & Johnson said the FDA approved Icotyde (icotrokinra) on March 18, 2026 for moderate-to-severe plaque psoriasis in adults and in pediatric patients 12 and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. The once-daily tablet is the first and only targeted oral peptide approved to block the IL-23 receptor, giving dermatology prescribers a new oral option in a market long shaped by injectables and, more recently, oral TYK2 inhibitors. J&J has positioned the launch as a first-line systemic option, and the approval follows a broad Phase 3 program that the company says enrolled about 2,500 patients across four studies. (investor.jnj.com)

Why it matters: For clinicians, the approval adds a new mechanism and formulation to the psoriasis toolbox: oral dosing, biologic-like efficacy claims from the sponsor, and a label that includes adolescents meeting the weight threshold. It also raises the competitive stakes in systemic psoriasis care. J&J has already reported Phase 3 data showing icotrokinra outperformed deucravacitinib on skin-clearance endpoints, while Takeda is advancing zasocitinib, another oral psoriasis candidate, after reporting late-breaking Phase 3 data at AAD 2026. That means access, payer positioning, comparative safety, and real-world persistence will matter almost as much as efficacy headlines. (investor.jnj.com)

What to watch: Watch for formulary decisions, label uptake in adolescents, and whether longer-term data and head-to-head positioning help Icotyde hold an edge as other oral entrants move toward FDA submission. (investor.jnj.com)